TickerFacts.

Moleculin Biotech, Inc. (MBRX): EBITDA

Operating income plus depreciation and amortization for the same annual period and currency, computed by TickerFacts from the filed figures. Not the company's adjusted EBITDA; a year without both inputs is left out.

-$25.01M
Year ended 2025-12-31
-$28.83M
Trailing 12 months to 2026-06-30
2016-12-31: -$3.88M2017-12-31: -$8.63M2018-12-31: -$14.96M2019-12-31: -$17.32M2020-12-31: -$19.54M2021-12-31: -$22.80M2022-12-31: -$30.51M2023-12-31: -$29.50M2024-12-31: -$26.52M2025-12-31: -$25.01M-$25.01M
2016-12-31 EBITDA (USD) 2025-12-31
Period endedEBITDAChange YoYSource filing
2025-12-31-$25.01Mn/m2026-03-18, From 2025-01-01
2024-12-31-$26.52Mn/m2026-03-18, From 2024-01-01
2023-12-31-$29.50Mn/m2025-03-21, From 2023-01-01
2022-12-31-$30.51Mn/m2024-03-22, From 2022-01-01
2021-12-31-$22.80Mn/m2023-03-22, From 2021-01-01
2020-12-31-$19.54Mn/m2022-03-24, From 2020-01-01
2019-12-31-$17.32Mn/m2021-03-24, From 2019-01-01
2018-12-31-$14.96Mn/m2020-03-19, From 2018-01-01
2017-12-31-$8.63Mn/m2019-02-21, From 2017-01-01
2016-12-31-$3.88Mn/a2018-03-28, From 2016-01-01

EBITDA at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedEBITDAChange YoY
Moleculin Biotech, Inc. (MBRX)2025-12-31-$25.01Mn/m
TherapeuticsMD, Inc. (TXMD)2025-12-31-$4.01Mn/m
Nature's Sunshine Products Inc (NATR)2025-12-31$38.59M+12.5%
Lisata Therapeutics, Inc. (LSTA)2025-12-31-$18.06Mn/m
Heron Therapeutics, Inc. (HRTX)2025-12-31-$224.0Kn/m
Teva Pharmaceutical Industries Ltd (TEVA)2025-12-31$3.16B+317.9%
Emmaus Life Sciences, Inc. (EMMA)2025-12-31$270.0Kn/m
GeoVax Labs, Inc. (GOVX)2025-12-31-$21.57Mn/m
Lifevantage Corp (LFVN)2026-06-30$8.87M-42.2%

Compare MBRX, TXMD, NATR, LSTA side by side · Screen every company in Pharmaceutical Preparations ↗